Download PDFPDF

1217 Efficacy and additional mechanism of action of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, in preclinical models of non-muscle invasive bladder cancer
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address